Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.
about
Recommended reading in population pharmacokinetic pharmacodynamicsCovariate pharmacokinetic model building in oncology and its potential clinical relevance.Proposals for model-based paediatric medicinal development within the current European Union regulatory frameworkPopulation pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis.The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.IVGTT glucose minimal model covariate selection by nonlinear mixed-effects approachExplaining variability in ciclosporin exposure in adult kidney transplant recipients.Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failureDynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial.Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients.Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf.Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoringPopulation pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.What is the best size descriptor to use for pharmacokinetic studies in the obese?Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patientsModelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters.Population pharmacokinetics of darbepoetin alfa in healthy subjectsModel-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?Time-course analysis of main markers of primary infection in cats with the feline immunodeficiency virus.Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypesModeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C VirusCharacterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study.Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.ADME pathway approach for pharmacogenetic studies of anti-HIV therapy.Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy.Importance of hematocrit for a tacrolimus target concentration strategy.Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics.Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from ten Phase I trials.Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention.Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis.Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models.Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.Quantitative Assessment of Food Effect on the Pharmacokinetics of Nano-Crystallized Megestrol Acetate.An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.Population Pharmacokinetics Modeling of Inhaled Umeclidinium for Adult Patients with Asthma.
P2860
Q24647906-9D6CF809-7E67-4B9A-8C57-EF15FA51D5AFQ27687599-4DF9CE40-0E7C-4109-967B-3FF32395454CQ28749999-4C4344A0-AD74-4E8D-9ECE-AB293DC3D73DQ31085591-25436C1D-909D-41EE-ADAD-9288A5088CB2Q33384661-46260947-D5C1-4C53-A4F0-9399F7F762DBQ33840340-888AC99A-6C7F-467E-A083-F8FD6652D3E2Q33847140-9971144F-E623-45E6-8C3D-DF8187BBB79DQ34206601-EAE4BB74-29EF-4653-85C6-E9F96D988F4CQ34348318-F21CB852-B180-4D7B-8B19-4B6A4B3313EAQ34554442-198BDA2F-67BE-4EBF-8189-9968C400931EQ34609009-A633593C-0514-451C-BDE9-AEF020C674D8Q34858098-D5DEC61F-870B-49D4-8E8D-FCEAA4080A8AQ35603293-949C6B2B-2EC2-4A75-A48D-5EE5B2C273D0Q35826324-8CDFB6DD-3234-4A95-A5F0-717055DE4AADQ35827635-B4B08AE5-2FE6-43D0-B5ED-E16DE3715AA9Q35968259-0DFCBA1B-387A-4E2F-AC9A-9D42E9E21B01Q36024876-1B3774A6-81F5-4253-B3C2-585922134E9BQ36111218-597621A3-E48A-46C2-BA10-45B15F65225DQ36158212-25DCFA94-F0C2-481E-BD18-59EF92E68F3FQ36294268-8A416780-4F32-4507-9CC3-B183DEBA36AEQ36410129-31C8258B-4294-402C-BA76-8D82471E3654Q36562471-33DD303C-7F53-4364-8ED7-453F20DAEC06Q36600070-D3474858-444B-4014-977E-AA9831538516Q36785991-7E6BC754-5F72-476A-B699-94EAF0B5DA83Q36837971-FB248A2D-AA5C-46A0-B706-56E787EE2964Q36845126-1D7A442F-CE85-4DF8-8257-19EEB408CDCAQ37094229-FDAF3F9C-8B78-4405-A7B8-F6090812481AQ37203867-82EE6071-99AB-4339-9EE5-C9203EFF64D3Q37385389-BB612404-7461-4CC8-A35D-49844E6A5E2EQ37469289-A5472353-1F90-475F-A73B-B1709BF10097Q38405565-8378856A-7CAF-4100-B628-01E9E270CD51Q38557882-EA7AEDB4-21E1-4B14-BB5E-BA1E3ADF617EQ38612177-9A30C16E-F182-4A86-8C63-4C335D8058C9Q38905356-4AF6753F-382F-4286-A37B-EC6FB25DCAADQ38913752-62C74EE9-598B-48F4-BFCD-0FF5B0CD92CEQ38987763-1EA9625F-B67E-4134-8443-799D40D03B4CQ38992758-6D9456E6-CC27-4E3D-AC6D-7042BFEC2701Q39379170-8E73EB35-DA10-4E22-9424-8521175FC5E8Q39740912-94D81C66-EA20-4E31-ADC7-4409391168AFQ39879277-4E6CF335-C06A-4D1B-A84F-D15BC42A0DD4
P2860
Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2002
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of stepwise covaria ...... etic-pharmacodynamic analysis.
@en
Comparison of stepwise covaria ...... etic-pharmacodynamic analysis.
@nl
type
label
Comparison of stepwise covaria ...... etic-pharmacodynamic analysis.
@en
Comparison of stepwise covaria ...... etic-pharmacodynamic analysis.
@nl
prefLabel
Comparison of stepwise covaria ...... etic-pharmacodynamic analysis.
@en
Comparison of stepwise covaria ...... etic-pharmacodynamic analysis.
@nl
P2093
P2860
P356
P1433
P1476
Comparison of stepwise covaria ...... etic-pharmacodynamic analysis.
@en
P2093
E Niclas Jonsson
Mats O Karlsson
Ulrika Wählby
P2860
P356
10.1208/PS040427
P577
2002-01-01T00:00:00Z